Related Experiment Video

Updated: Jul 17, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic

P Caini1, C Tosti Guerra, C Giannini

  • 1Department of Internal Medicine, Center for the Study of Systemic Manifestations of Hepatitis Viruses MASVE and Higher Education Research and Transfer Center DENOTHE, University of Florence, Florence, Italy.

Journal of Viral Hepatitis
|January 11, 2007
PubMed

Insights

Chronic Hepatitis C virus (HCV) infection alters the platelet-activating factor (PAF) system, increasing PAF levels and decreasing PAF-acetylhydrolase (pPAF-AH) activity. Viral clearance restores this crucial inflammatory balance.

Area of Science:

  • Virology
  • Immunology
  • Biochemistry

Background:

  • Hepatitis C virus (HCV) causes chronic liver and lymphatic diseases in millions globally.
  • HCV circulates in serum, linked with apoB lipoproteins.
  • Platelet-activating factor (PAF) is a pro-inflammatory mediator regulated by plasma PAF-acetylhydrolase (pPAF-AH), which is associated with LDL.

Purpose of the Study:

  • To investigate the impact of chronic HCV infection on the PAF/pPAF-AH system.
  • To determine if HCV affects PAF levels and pPAF-AH activity.

Main Methods:

  • HCV-RNA detection in plasma, PBMCs, and liver samples.
  • Quantification of plasma PAF levels and pPAF-AH activity.
  • Measurement of ApoB100 serum titres and pPAF-AH mRNA in macrophages.

Main Results:

  • HCV patients exhibited significantly higher plasma PAF levels and lower pPAF-AH activity compared to controls.
  • No significant changes in pPAF-AH mRNA in macrophages or ApoB100 levels were found in HCV patients.
  • Antiviral treatment leading to HCV clearance resulted in restored pPAF-AH activity and decreased PAF levels.

Conclusions:

  • Chronic HCV infection significantly alters the PAF/pPAF-AH system.
  • HCV clearance reverses these alterations, suggesting circulating viral particles influence the system.
  • Dysregulation of the PAF/pPAF-AH system may contribute to HCV-related tissue damage.

More Related Videos

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...